Serclutamab

Serclutamab Suppliers list
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 13636370518
Email: shyysw007@163.com
Products Intro: Product Name:Serclutamab (anti-EGFR)
CAS:2140172-41-2
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K14119
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com
Products Intro: Product Name:Serclutamab
CAS:2140172-41-2
Purity:95% Package:100ug;500ug;1mg
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Products Intro: Product Name:Serclutamab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
Company Name: Biolab Reagents  
Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Products Intro: Product Name:Research Grade Serclutamab(DHB86915)
CAS:2140172-41-2
Purity:PAGE:>95% Package:100ug;1mg
Company Name: Wuhan Jingkangen Biomedical Technology Co., Ltd  
Tel: 13720134139 086-15871494362 13720134139
Email: orders@jknbiochem.com
Products Intro: Product Name:Serclutamab
CAS:2140172-41-2
Purity:95% Package:100ug:500ug:1mg
Serclutamab Basic information
Product Name:Serclutamab
Synonyms:Serclutamab;Research Grade Serclutamab(DHB86915);Research Grade Serclutamab;Serclutamab (anti-EGFR);DC-1630423;PR-1594407;Immunoglobulin G1[238-cysteine], anti-(human epidermal growth factor receptor) (human-Mus musculus monoclonal ABT-806 AM1 S238C γ1-chain), disulfide with human-Mus musculus monoclonal ABT-806 AM1 S238C κ-chain, dimer (ACI)
CAS:2140172-41-2
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Serclutamab Structure
Serclutamab Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Serclutamab Usage And Synthesis
UsesSerclutamab is a humanized chimeric antibody targeting EGFR IgG1-κ. Mainly expressed by CHO (Chinese Hamster Ovary) cells[1].
References[1] Serclutamab. IMGT.
Serclutamab Preparation Products And Raw materials
Tag:Serclutamab(2140172-41-2) Related Product Information
Narlumosbart citatuzumab Lebrikizumab Namilumab Urtoxazumab Toripalimab Rituximab Emapalumab Lodelcizumab Magrolimab